HR positive

In addition, WWZ-11-098 displayed favorable pharmacokinetic properties (Cmax = 11833 ng/mL, T1/2 = 2.64 h after a 5 mpk IV dose) and exhibited robust antitumor efficacy (TGI: 77.1 % @10 mpk) in a MOLT-4 xenograft model without signs of toxicity. The compound provides not only a valuable chemical probe but also a lead structure for further development of CDK6 degraders.

The median progression-free survival was 34, 12, and 8 months for BRCA-negative, BRCA1-, and BRCA2-positive groups, respectively (p = 0.001). To our knowledge, this is the first comprehensive analysis of BRCA1/2 mutation profiles among Kazakhstani women, highlighting distinct genotype-phenotype correlations and supporting the need for personalized therapeutic strategies in this population.

In the CAPItello-291 trial, capivasertib and fulvestrant demonstrated efficacy in patients with up to two prior lines endocrine therapy, but its use in late-line settings has not yet been reported. In this article, we report a case of a woman with metastatic recurrent breast cancer who was treated with capivasertib and fulvestrant was used as the late-line treatment, resulting in a progression-free survival of 8 months.

One PD and 6 adverse events were the reasons for switching to ABM after taking PLB. Although the number of patients was small, PFS with sequential CDK4/6 inhibitors could be expected to be longer than 6 months, suggesting that the treatment may be useful in extending the time to chemotherapy induction.

Partial resections were treated with radiation:only invasive case was treated with endocrine therapy. Rapid growth and high proliferative activity was noted in patients with invasive EPC;this suggests the need to carefully monitor the prognosis of such patients.

After irradiation to the pain area, paclitaxel and bevacizumab therapy was administered, and a marked reduction of pulmonary and liver metastases, and the disappearance of pain were observed. Local hepatic therapy with TAE followed by chemotherapy was thought to have helped the patient overcome the rapid tumor growth.

Postoperatively, tamoxifen, a CDK4/6 inhibitor, and radiotherapy were administered...Despite initiating weekly paclitaxel plus bevacizumab, the disease progressed rapidly, and she died 4 months later. Notably, OMS symptoms did not recur. This case highlights paraneoplastic OMS as an initial manifestation of breast cancer, with neurological improvement following systemic therapy.

Three lymph node metastases were identified. Oncotype DX was performed but was judged inconclusive due to insufficient tumor tissue.

After surgery, chemotherapy followed by endocrine therapy was administered, and tumor markers decreased, and bone metastases remained stable disease(SD). Two years and 2 months after surgery, no local recurrence or appearance of new lesions have been observed.

The FROST trial adds to the growing body of literature supporting the efficacy and safety of cryoablation and supports ongoing research on cryoablation as a strategy for de-escalating breast cancer therapy.

Individual patient coaching based on MOAT